Allergan Inc. (NYSE:AGN.)

Net Earnings Trends

The reported net earnings attributable to the company exhibited significant growth over the five-year period. Starting at a relatively low base of 600 thousand US dollars in 2010, earnings surged to 934,500 thousand US dollars in 2011. This upward trajectory continued with net earnings reaching approximately 1,098,800 thousand in 2012. A slight decline occurred in 2013, where earnings decreased to 985,100 thousand US dollars. In 2014, the earnings rebounded strongly, increasing to 1,524,200 thousand US dollars, representing the highest value in the period analyzed.

Adjusted Net Earnings Trends

Adjusted net earnings closely mirrored the pattern seen in reported net earnings. The adjustments made did not significantly deviate from the reported values, indicating that the adjustments were minimal or non-material in nature. Adjusted earnings increased from 600 thousand US dollars in 2010 to 934,500 thousand in 2011 and then to 1,098,800 thousand in 2012. A mild reduction was observed in 2013, with adjusted earnings at 985,100 thousand US dollars. In 2014, adjusted earnings slightly exceeded reported earnings, reaching 1,530,000 thousand US dollars, which suggests that adjustments had a positive impact in that year.

Overall Insights

The data indicates a robust growth trajectory in both reported and adjusted earnings over the five years, with a minor setback in 2013. The close alignment between reported and adjusted net earnings suggests consistent accounting practices or limited extraordinary items requiring adjustment. The substantial increase in 2014 net earnings may reflect improved operational performance, cost efficiencies, or favorable market conditions during that year. This pattern highlights the company’s capacity for earnings growth despite short-term fluctuations.

Net Profit Margin Trends

The net profit margin exhibited a substantial increase from a negligible level of 0.01% in 2010 to a significant peak of 21.39% in 2014. The margin showed steady growth through 2011 and 2012, reaching 19.25%, followed by a slight decline to 15.9% in 2013 before rebounding in 2014. The adjusted net profit margin closely mirrored the reported margin, indicating consistent adjustments over the observed period.

Return on Equity (ROE) Patterns

Reported ROE experienced notable improvement from 0.01% in 2010 to a high of 19.66% by the end of 2014. The trajectory included growth to nearly 18.82% in 2012, a dip to 15.24% in 2013, and subsequent recovery in 2014. Adjusted ROE values aligned closely with reported figures, signaling that investment adjustments had minimal impact on ROE trends during the analyzed timeframe.

Return on Assets (ROA) Dynamics

The ROA demonstrated an overall positive trend starting from 0.01% in 2010, increasing to 11.97% in 2012. Despite a decrease to 9.32% in 2013, the ROA rose again to 12.28% in 2014. Adjusted ROA closely followed the reported ROA, with slight variances, reflecting consistent adjustments and stable asset utilization efficiency.

Overall Observations

From 2010 to 2014, all key profitability and efficiency ratios—net profit margin, ROE, and ROA—showed significant improvement, indicating enhanced operational performance and financial management. The temporary decline in 2013 across all metrics suggests a possible short-term setback or external challenge. The close alignment between reported and adjusted figures throughout the period implies that non-recurring items or accounting adjustments did not substantially affect the core financial performance metrics.

The financial data reveals significant growth in net earnings and net profit margins for Allergan Inc. over the five-year period ending December 31, 2014. Both reported and adjusted net earnings exhibit a similar upward trend.

Net Earnings

Reported net earnings increased markedly from US$ 600 thousand in 2010 to US$ 1,524,200 thousand in 2014, indicating substantial improvement in profitability. Adjusted net earnings closely follow the same pattern, rising from US$ 600 thousand in 2010 to US$ 1,530,000 thousand in 2014, suggesting that adjustments made to the reported figures have minimal impact on the overall earnings trend.

Net Profit Margin

The reported net profit margin showed a considerable rise from a negligible 0.01% in 2010 to 21.39% in 2014. The adjusted net profit margin mirrors this trajectory, increasing from 0.01% to 21.47% by 2014, further confirming the consistency between reported and adjusted profitability measures.

Year-Over-Year Trends

From 2010 to 2011, the data shows a dramatic escalation in both net earnings and profit margins, with earnings jumping from 600 to over 900 million US dollars and margin improving from nearly zero to over 17%. Following 2011, net earnings and profit margins continue a general upward trend with slight fluctuations; net earnings peaked in 2012 at approximately 1.1 billion US dollars, experienced a minor dip in 2013, then reached the highest value in 2014. Profit margins reflect a similar pattern, peaking in 2012 at 19.25%, declining in 2013 to 15.9%, and recovering strongly in 2014 to above 21%.

Overall Insights

The company demonstrates robust financial improvement, with reports indicating enhanced profitability and significant expansion in net earnings. The close alignment between reported and adjusted figures suggests reliable financial reporting practices and stable earnings quality. The recovery in profit margin in 2014 after the dip in 2013 may reflect successful operational improvements or favorable market conditions during that period.

The financial data for Allergan Inc. over the period from December 31, 2010, to December 31, 2014, reveals notable trends in net earnings and return on equity (ROE), both on a reported and adjusted basis.

Net Earnings

Reported net earnings attributable to the company showed a significant increase from 600 thousand US dollars in 2010 to 934,500 thousand in 2011, marking a substantial growth during this period. This upward trend continued with earnings reaching 1,098,800 thousand in 2012. However, a decline was observed in 2013, with earnings decreasing to 985,100 thousand. In 2014, the net earnings rose again, achieving a peak of approximately 1,524,200 thousand US dollars, indicating a strong recovery and impressive growth overall.

The adjusted net earnings mirrored the reported figures closely, with the only slight variation in 2014, where the adjusted net earnings were marginally higher at 1,530,000 thousand US dollars compared to the reported figure. This close alignment suggests that adjustments made had minimal impact on the overall earnings presentation.

Return on Equity (ROE)

Reported ROE experienced a dramatic increase from an extremely low 0.01% in 2010 to 17.6% in 2011, reflecting improved efficiency in generating profits from shareholders' equity. The ROE continued to improve, peaking at 18.82% in 2012. This was followed by a decline to 15.24% in 2013, indicating some reduction in earnings relative to equity during that year. By 2014, ROE rebounded strongly to nearly 19.66%, further highlighting the company’s enhanced profitability and effective utilization of equity capital.

The adjusted ROE tracked the reported ROE very closely, with only a minor difference in 2014 where the adjusted ROE was slightly higher at 19.73%. This consistency further supports the reliability of the financial metrics presented.

Overall, the company demonstrated robust growth in earnings and profitability from 2010 through 2014, with only a minor dip in 2013. Both reported and adjusted financial measures show strong alignment, indicating stable and reliable reporting practices. The rebound in 2014 to the highest levels within the given timeframe underscores successful financial performance and effective management of equity capital.

Net Earnings Attributable to Allergan, Inc.

The reported net earnings exhibited a significant increase from 600 thousand US dollars in 2010 to approximately 934.5 million in 2011, continuing to rise to about 1.1 billion in 2012. There was a decline noted in 2013 to nearly 985.1 million, followed by a substantial recovery and growth to approximately 1.52 billion in 2014. The adjusted net earnings followed a similar pattern, closely mirroring the reported figures, with a slight increase in 2014 compared to the reported net earnings.

Return on Assets (ROA)

The reported ROA showed a minimal figure of 0.01% in 2010, which then surged dramatically to 10.98% in 2011. It increased further to 11.97% in 2012 before declining to 9.32% in 2013. In 2014, ROA improved again to above 12%, indicating enhanced asset profitability. The adjusted ROA closely parallels the reported ROA throughout the period, with a marginally higher figure in 2014, reflecting slight adjustments in asset efficiency calculations.

Overall Trends and Insights

The financial performance reflects strong growth and recovery phases across the analyzed years. The most notable changes occur between 2010 and 2011, where earnings and asset returns experienced exponential growth. The dip in 2013 suggests a period of operational or market challenges, which was effectively overcome by 2014, given the improved profitability metrics. The close alignment between reported and adjusted figures indicates consistent accounting practices with minor adjustments applied in 2014.